Drug-Eluting Stents Market: A Global Strategic Business Report
San Jose, CA (PRWEB) February 28, 2008
Increasing acceptance of stents as viable treatment option, expanding patient population seeking drug-eluting stents, and higher reimbursement coverage are key factors driving growth of drug-eluting stents. The global drug-eluting stents market is likely to grow and reach US$5.7 billion by 2015, as stated in a recent report published by Global Industry Analysts, Inc. The United States represents the leading regional market, capturing over 53% of worldwide sales. However, with the maturity of the DES market characterized by high penetration, the US is expected to witness the least growth through 2015. Additionally, recent incidents of adverse effects such as in-stent thrombosis developed as a result of using DES is expected to further dent the market growth. The European market has been relatively slow on the uptake mainly as a result of high price of stents and lower medical reimbursement rates in the region. Japan on the other hand, is a very new entrant into the market, the first DES product released only in late 2004.
Development of innovative treatment methods and preventive measures for coronary diseases, obesity, and diabetes are few factors influencing the long-term growth prospects of the drug-eluting stents market. However, adverse effects such as in-stent thrombosis by the use of drug-eluting stents, lower reimbursement levels, limited resources of national health care organizations in regions other than United States, arduous regulatory framework, high costs of the products and inflexible healthcare systems are some of the important issues that are inhibiting growth in the industry.
Drug-eluting stents registered significant growth in the recent past. However, recent incidents of adverse effects such as in-stent thrombosis is expected to significantly restrict future market growth. In-stent thrombosis is a common long-term adverse effect of DES where patients develop clots. Owing to the rise in in-stent thrombosis cases, major DES manufacturers such as J&J and Boston Scientific are experiencing hefty decline in sales. Although in-stent thrombosis cases occur rarely, they are highly fatal. On the contrary, bare-metal stents do not pose such threats thereby augmenting its usage in interventional management. The rise in in-stent thrombosis cases paves the way for anti-thrombotic therapies. Moreover, drug-eluting stents faces stiff competition from advanced and safer technologies such as tiny wire mesh tubes.
Major players in the marketplace include Abbott Vascular, AngioDynamics, Angiotech Pharmaceuticals, Boston Scientific, Biocompatibles International, Biosensors International, Cordis, Implant Sciences, Medtronic, MIV Therapeutics, and SurModics.
"Drug-Eluting Stents Market: A Global Strategic Business Report", published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, product profile, recent developments, mergers, acquisitions, profiles of major players and other strategic industry activities. Analysis is presented for major geographic markets such as US, Japan, France, Germany, Italy, the UK, Spain, and rest of world. Analytics are presented for the period 2003 through 2015.
For more details about this research report, please visit http://www.strategyr.com/Drug-Eluting_Stents_Market_Report.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/